<title>Background</title> <p>Preeclampsia, a pregnancy-specific syndrome affecting about 5% to 10% of all pregnancies, is characterized by hypertension and proteinuria after 20 weeks of gestation. It is a major cause of maternal and perinatal morbidity and mortality and occurs only in the presence of a placenta and remits dramatically after the placenta has been delivered. The underlying pathogenetic mechanisms of this maternal syndrome are much debated with the current hypotheses including inflammatory disease, vascular-mediated factors, placental ischemia, genetic predisposition and immune maladaptation [##REF##598186##1##, ####REF##2589440##2##, ##REF##10985960##3####10985960##3##]. Preeclampsia is also associated with defective uteroplacental vascularization [##REF##9539527##4##] and impairment of angiogenesis and vascular transformation of the uteroplacental unit, which are crucial for normal fetal development [##REF##11141345##5##]. However, the molecular pathways responsible for normal angiogenesis and vascular remodeling in the fetomaternal unit are still poorly understood.</p> <p>Vascular endothelial growth factor (VEGF) is a major angiogenic factor and plays an important role in all aspects of vascular development, including endothelial cell proliferation, migration, survival and regulation of vascular permeability [##REF##10494799##6##,##REF##11001067##7##]. VEGF and its two receptors, fms-like tyrosine kinase 1 (Flt-1) (VEGFR-1) and KDR/Flk-1 (VEGFR-2), have been shown to be part of an essential regulatory system for blood vessel formation. One of the two receptors, Flt-1 appears to have dual functions, with negative and positive activity in vascular endothelial cells. In early embryogenesis, Flt-1 functions as a negative regulator, most likely through its strong VEGF trapping activity [##REF##9689083##8##]. Flt-1 (-/-) mice are embryonic lethal due to the disorganization of blood vessels and overgrowth of endothelial-like cells within the lumens of blood vessels [##REF##7596436##9##]. In adult stages, however, Flt-1-specific ligand can induce a mild angiogenesis. Thus, this dual function may be tightly regulated and important for fine tuning the formation and maintenance of the blood vessel structure in placental vasculature.</p> <p>During placental development, the expression of the Flt-1 gene is not only detected in vascular endothelial cells, but also in the developing trophoblasts [##REF##8671397##10##]. The Flt-1 gene is located in the chromosome region 13q12 and consists of 30 exons and 29 introns [##REF##2158038##11##,##REF##9524283##12##]. The gene encodes a high affinity receptor for VEGF, which has sixth immunoglobulin (Ig)-like domains in the extracellular region based on the distribution of cysteine residues, a transmembrane domain and an intracellular region containing a tyrosine kinase domain divided by a long kinase-insert domain [##REF##2158038##11##,##REF##8248162##13##]. There is a dinucleotide repeat in the 3' non-coding region of the Flt-1 gene [##REF##2158038##11##] that has been shown to be polymorphic [##REF##2041764##14##,##REF##8111406##15##]. This region of the gene codes for the intracellular part of the protein that is likely associated with signal transduction. Dinucleotide repeat regions are often used as disease markers and their functional significance is being increasingly realized [##REF##8827368##16##,##REF##9393771##17##]. Considering the important roles of Flt-1 in pregnancy, functional polymorphisms in the Flt-1 gene may be potentially important as genetic markers for susceptibility to preeclampsia. Based on genetic predisposition, this relationship may be strengthened by showing an association between polymorphisms of Flt-1 gene and an increased risk of developing preeclampsia. In view of the possible role of the Flt-1 gene in the etiology of preeclampsia, we investigated whether the dinucleotide (threonine-glycine; TG)<sub>n </sub>repeat polymorphism in the 3' non-coding region of the Flt-1 gene is associated with preeclampsia in Korean pregnant women.</p>
<title>Methods</title> <title>Subjects</title> <p>All subjects were recruited from the Obstetrics and Gynecology Department at Cheil General Hospital between October 2001 and June 2004. The study population included 170 patients with preeclampsia (13 mild and 157 severe) and 202 sampling week-matched normal pregnancies of Korean origin. Preeclampsia was defined as hypertension (systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg after 20 weeks' gestation) and proteinuria (≥ 300 mg in a 24 h urine collection or ≥ 1+ on dipstick testing) according to the criteria of the National High Blood Pressure Education Program Working Group Report on High Blood Pressure in Pregnancy [##UREF##0##18##]. Severe preeclampsia was diagnosed on the basis of diastolic blood pressure ≥ 110 mmHg or significant proteinuria (dipstick measurement of ≥ 2+) or the presence of headache, visual disturbances, upper abdominal pain, oliguria, convulsion, elevated serum creatinine, thrombocytopenia, marked liver enzyme elevation or pulmonary edema [##UREF##0##18##]. Only one woman was a HELLP syndrome in preeclamptic patients. Exclusion criteria included major congenital anomalies, fetal chromosomal abnormalities, chronic hypertension, diabetes or renal disease. Controls were selected randomly from contemporaneous women who were normotensive and who were without proteinuria throughout pregnancy, and who delivered a healthy neonate at term without significant medical or obstetric complications (including intrauterine growth retardation; IUGR). IUGR was defined as a birth weight less than the 10th percentile for gestational age. Written informed consent was obtained from all subjects before blood sampling, which was approved by the Ethics Committee of Cheil General Hospital and Women's Health Care Center.</p> <title>DNA Sequencing</title> <p>Peripheral blood was collected in EDTA vacutainer tube (Becton Dickinson, USA) for genomic DNA isolation. Genomic DNA was extracted from whole blood using a QIAamp DNA Blood Mini Kit (Qiagen GmbH, Hilden Germany) according to the manufacturer's recommendations. A genomic fragment containing the d(TG)<sub>n </sub>repeat polymorphism of the Flt-1 gene was amplified by polymerase chain reaction (PCR) using the fluorescent 6FAM-labelled forward primer 5'-6FAM-TTTGGCCGACAGTGGTGTA-3' and the unlabelled reverse primer 5'-CTTTAAAATTCCAGTTTCCTT-3', according to Parry [##REF##10553496##19##]. PCR reactions were performed in a final volume of 20 ul containing 10 ng of genomic DNA, 2 ul of 10× PCR buffer (Applied Biosystems, Foster City, CA, USA), 1.25 mM MgCl<sub>2 </sub>(Applied Biosystems), 1 mM of each dNTP (Applied Biosystems), 10 pmol of each specific primer and 1 U of Taq DNA Polymerase (Applied Biosystems). The PCR conditions consisted of an initial denaturation at 95°C for 5 min, followed by 33 cycles of denaturation at 95°C for 40 s, annealing at 55°C for 40 s, extension at 72°C for 40 s, and a final extension at 60°C for 30 min on ABI PRISM 2700 thermal cycler (Applied Biosystems). An aliquot of the amplified PCR product was electrophoresed on a 3% neusive gel to verify product quality and quantity.</p> <p>PCR products were purified with AccuPrep<sup>® </sup>PCR purification kit (BIONEER, Korea) and the purified PCR products were sequenced with an ABI PRISM BigDye Terminator Cycle Sequencing Kit (Applied Biosystems). The number of TG repeats within each allele was analyzed by direct sequencing using an ABI PRISM 3100 Genetic Analyzer (Applied Biosystems). The electropherogram traces were interpreted by Genescan software version 3.7 (Applied Biosystems) and corresponding genotypes assigned using Genotyper software version 3.7 (Applied Biosystems). All samples were analyzed twice to confirm the integrity of the results.</p> <title>Statistical Analysis</title> <p>Data were expressed as the mean ± SD, median (range) or number (%). The Student's <italic>t</italic>-test was used for comparison of continuous variables between normal controls and preeclamptic patients. Categorical variables, such as the comparison in the allele and genotype frequencies between the two groups, were analyzed by a 2 × 2 Chi-Squared test or Fisher's exact test. Odds ratios (OR) and 95% confidence intervals (CI) were calculated to assess the disease risk conferred by genotypes. Hardy-Weinberg equilibrium was tested in patients 0.05 was considered statistically significant. and controls, separately, by means of the Chi-Squared analysis <ext-link ext-link-type="uri" xlink:href="http://www.fourmilab.ch/rpkp/experiments/analysis/chiCalc.html"/>. A <italic>p </italic>value &lt; 0.05 was considered statistically significant. The statistical analysis was performed with the Statistical Package for Social Sciences version 10.0 (SPSS Inc., Chicago, USA).</p>
<title>Results</title> <p>Polymorphism analysis of the Flt-1 gene was performed for 170 preeclamptic patients and 202 normotensive pregnancies. The clinical characteristics of the study population are shown in Table ##TAB##0##1##. Maternal age, nulliparity, blood pressure, maternal weight at delivery, gestational age at delivery and birth weight were found to be significantly different between the two groups (<italic>p </italic>&lt; 0.05). In addition, 58 (34.12%) of the 170 preeclamptic patients delivered a fetus with IUGR, defined as birth weight below the 10th percentile for gestational age.</p> <p>Ten alleles observed in this study groups were designated as allele*12 (A1) through allele*23 (A12), according to the number of TG repeats, which ranged in size from 102 bp (12 TG repeats with a 78 bp segment of amplified flanging sequences) to 124 bp (23 TG repeats) (Table ##TAB##1##2##). The frequency of the 14-repeat allele (A3) was most abundant (63.82% in preeclampsia and 69.06% in controls), followed by the 21-repeat allele (A10; 28.53% in preeclampsia and 23.76% in controls) (Table ##TAB##1##2##). The allele frequency was very similar to that previously reported for an American population [##REF##2041764##14##]. Interestingly, the 12-, 15-, 19-, and 20-repeat alleles had not previously been reported. However, the allele frequencies of the Flt-1 (TG)<sub>n </sub>polymorphism in patients with preeclampsia did not differ from those in normal controls. Furthermore, the genotype frequencies in preeclampsia and controls did not significantly deviate from Hardy-Weinberg equilibrium (data not shown). The genotypes were classified into five groups; (TG)<sub>14</sub>/(TG)<sub>14</sub>, (TG)<sub>14</sub>/(TG)<sub>21</sub>, (TG)<sub>21</sub>/(TG)<sub>21</sub>, Other, Combination (Table ##TAB##2##3##). The most common genotype in normal controls (45.05%) was homozygous (TG)<sub>14</sub>/(TG)<sub>14</sub>, whereas those in preeclamptic patients (41.76%) was heterozygous (TG)<sub>14</sub>/(TG)<sub>21 </sub>(Table ##TAB##2##3##). We compared each reference group [(TG)<sub>14</sub>/(TG)<sub>14</sub>, (TG)<sub>14</sub>/(TG)<sub>21</sub>, or (TG)<sub>21</sub>/(TG)<sub>21 </sub>genotype] with Other (Table ##TAB##2##3##). Additionally, we also compared (TG)<sub>14</sub>/(TG)<sub>14 </sub>genotype with the combined genotype [(TG)<sub>14</sub>/(TG)<sub>21</sub>+(TG)<sub>21</sub>/(TG)<sub>21</sub>+Other] (Table ##TAB##2##3##). However, the genotype frequencies of the Flt-1 (TG)<sub>n </sub>polymorphism in preeclamptic patients did not differ from those in normotensive pregnancies.</p>
<title>Discussion</title> <p>Microsatellites are powerful tools for performing linkage and association studies for diseases but they may also be directly involved in the modification of gene expression levels by silencing/enhancing transcription and modulating splicing events [##REF##11179974##20##,##REF##10224073##21##]. Since the microsatellite is located within intronic sequence with no obvious functional relevance, as shown by Turecki [##REF##9857980##22##], it is possible that specific alleles of this repeat may be in linkage disequilibrium with a nearby polymorphism that affects disease susceptibility. Moreover, variability in simple intronic repeats is probably involved in the etiology and pathogenesis of multifactorial diseases [##REF##9050930##23##].</p> <p>However, although genetic factors have been extensively investigated during the past decade [##REF##11197372##24##], the dissection of the genetic basis for preeclampsia has been challenged by the wide clinical heterogeneity of this disorder and the lack of a full understanding of its underlying cause. The genes expressed in the placental vasculature throughout pregnancy are attractive candidate genes and nearly all accessible genes have been extensively analyzed. The Flt-1, a major receptor for VEGF, is produced as a 1338 amino acid residue precursor with a predicted 22 amino acid signal peptide. The extracellular domain of Flt-1 is composed of 736 amino acids; its transmembrane spanning domain is 22 amino acids and its intracellular domain is 558 amino acids. Spongiotrophoblast cells, endothelial cells and their progenitors are the major placental source of Flt-1 [##REF##1729274##25##,##REF##7692439##26##]. Given the regulatory role of Flt-1 in pregnancy and the presence of a multiallelic polymorphism in the Flt-1 gene, Flt-1 could conceivably be a candidate susceptibility gene in preeclampsia.</p> <p>In this study, we focused on a d(TG)<sub>n </sub>repeat polymorphism in the Flt-1 gene which may be associated with preeclampsia in Korean pregnant women. First, the Flt-1 gene contains a polymorphic TG dinucleotide repeat in the 3' non-coding region that might affect signal transduction. Secondly, decreased Flt-1 expression has been shown in the placental bed of preeclamptic patients [##REF##14602804##27##]. The down-regulation of Flt-1 in the placental bed may result in a decreased maternal vascular adaptation to pregnancy [##REF##14602804##27##]. Third, the production of the soluble, alternatively spliced Flt-1, sFlt-1, is significantly higher in preeclamptic patients compared with normotensive pregnant women [##REF##12727995##28##]. Finally, the embryos of Flt-1 mutant mice develop vasculature through endothelial cell differentiation. This vasculature is highly abnormal and unorganized with an overgrowth of endothelial cells crowding the lumen [##REF##11221852##29##].</p> <p>Polymeropoulos [##REF##2041764##14##] first demonstrated that a higher percentage of 50 individuals from an American population had the 14-repeat allele of the (TG)<sub>n </sub>polymorphism in the 3' non-coding region of the Flt-1 gene. They also observed that the distribution of the (TG)<sub>n </sub>repeat alleles was bimodal, with two peaks at 14 repeats and 21 repeats, respectively. In this study, we tested, for the first time, the association between preeclampsia and the TG dinucleotide repeat polymorphism in the 3' non-coding region of the Flt-1 gene. Our data reveals that two alleles (14-repeat and 21-repeat) predominate in both preeclamptic and normal pregnancies, similar to the observation of Polymeropoulos [##REF##2041764##14##]. However, we could not find any differences in the allele or genotype frequencies of Flt-1 between preeclamptic patients and normal controls. This polymorphism of the Flt-1 gene was also studied by Parry et al. in minimal change nephropathy (MCN) patients compared to the standard American population [##REF##10553496##19##]. The investigators hypothesized that misregulation of Flt-1 may provide a mechanism for the development of protenuria in MCN, thus, polymorphisms in this gene may predispose to MNC. However, they did not demonstrate any deviation in the allele frequency in patients with MNC, implying that this locus does not contribute to susceptibility to MCN. Furthermore, we found that this dinucleotide polymorphism is not associated with a predisposition to preeclampsia. Alternatively, the penetrance of the Flt-1 gene may be modified by other factors, including distinct genetic loci that impart susceptibility.</p> <p>Flt-1 can be activated by VEGF and placental growth factor (PlGF), which are highly expressed in the placenta. Most of the Flt-1 produced in the mouse and human placenta during later stages of gestation is the soluble form (sFlt-1) generated by alternative splicing of Flt-1, leading to a premature termination after the sixth Ig-like domain [##REF##10194760##30##]. sFlt-1 binds both VEGF and PlGF and acts as a soluble antagonist of their action. Flt-1 misregulation in peripheral blood mononuclear cells of pregnant women can result in the over-expression of sFlt-1, which may produce an additional (extra-placental) source of sFlt-1 that contributes to the etiology of preeclampsia [##REF##15993706##31##]. A recent report showed that levels of maternal sFlt-1 were elevated in preeclampsia and that administration of sFlt-1 to pregnant rats can cause symptoms of preeclampsia with glomerular endotheliosis [##REF##12618519##32##]. This idea clearly suggests that placental Flt-1 can play roles in regulating maternal vasculature during pregnancy. We have previously shown that sFlt-1 levels in the second trimester maternal plasma are significantly higher in women with preeclampsia than in normal pregnant women [##REF##17982238##33##]; however, we were unable to demonstrate an association between the d(TG)<sub>n </sub>polymorphism in the 3' non-coding region of the Flt-1 gene and sFlt-1 levels. </p> <p>Most common genetic disorders, such as preeclampsia, follow a complex mode of inheritance and may result from variants of many genes, each contributing only a weak effect to the disease. Common genetic polymorphism may explain a portion of the heritable risk for common diseases. Consequently considerable effort should be devoted to finding and typing common microsatellite polymorphisms in the human genome in order to understand the occurrence of relatively common phenotypes. As trophoblast cells, which also express Flt-1, are fetal of origin, the role of fetal Flt-1 (TG)<sub>n </sub>polymorphism needs also to be examined in the risk of preeclampsia. Although we do not deny that one of the possible limitations of this case-control study is the relatively small sample size, we did take into account several issues that could lead to a false conclusion, such as established criteria for the diagnosis in order to exclude subphenotypes known to differ in the evaluation of the disease [##UREF##1##34##] and matching of cases and controls for several risk factors and for genetic background.</p>
<title>Conclusion</title> <p>To our knowledge, this is the first study investigating the association between the d(TG)<sub>n </sub>repeat polymorphism in the 3' non-coding region of the human Flt-1 gene [##REF##2041764##14##,##REF##8111406##15##,##REF##10553496##19##] and preeclampsia. In the present study, allele and genotype frequencies of this dinucleotide repeat polymorphism were not different between preeclamptic and normal pregnancies. Our results suggest that the Flt-1 (TG)<sub>n </sub>polymorphism is not associated with susceptibility to the development of preeclampsia in Korean pregnant women. This result might be indicative of the large diversity in the genetic background of preeclampsia, although this observation deserves further analysis in a larger group of preeclamptic patients.</p>
<p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p> <title>Background</title> <p>Preeclampsia is a major cause of maternal and perinatal mortality and morbidity. The etiology of preeclampsia remains unclear. Recently, it was shown that misregulation of fms-like tyrosine kinase-1 (Flt-1) in the peripheral blood mononuclear cells of pregnant women results in over-expression of the soluble splice variant of Flt-1, sFlt-1, producing an additional (extra-placental) source of sFlt-1 that can contribute to the etiology of preeclampsia. The aim of this study was to investigate the relationship between preeclampsia and a dinucleotide (threonine-glycine; TG)<sub>n </sub>repeat polymorphism in the 3' non-coding region of the Flt-1 gene.</p> <title>Methods</title> <p>The number of the d(TG)<sub>n </sub>repeats was analyzed in 170 patients with preeclampsia and in 202 normotensive pregnancies. The region containing the dinucleotide repeat polymorphism of the Flt-1 gene was amplified by polymerase chain reaction (PCR) from the DNA samples and was analyzed by direct PCR sequencing.</p> <title>Results</title> <p>We found 10 alleles of the dinucleotide repeat polymorphism and designated these as allele*12 (A1) through allele*23 (A12) according to the number of the TG repeats, from 12 to 23. The frequency of the 14-repeat allele (A3) was most abundant (63.82% in preeclampsia and 69.06% in controls), followed by the 21-repeat allele (A10; 28.53% in preeclampsia and 23.76% in controls). There was no significant difference in the allele frequency between patients with preeclampsia and normal controls. The most common genotype in preeclamptic and normotensive pregnancies was heterozygous (TG)<sub>14</sub>/(TG)<sub>21 </sub>(41.76%) and homozygous (TG)<sub>14</sub>/(TG)<sub>14 </sub>(45.05%), respectively. However, the genotype frequencies were not significantly different between preeclamptic patients and controls.</p> <title>Conclusion</title> <p>This is the first study to characterize the dinucleotide repeat polymorphism of the Flt-1 gene in patients with preeclampsia. We found no differences in the allele or genotype frequencies between patients with preeclampsia and normal pregnancies. Although limited by a relatively small sample size, our study suggests that the d(TG)<sub>n </sub>repeat polymorphism of the Flt-1 gene is not associated with the development of preeclampsia in Korean pregnant women.</p>
<title>Competing interests</title> <p>The authors declare that they have no competing interests.</p> <title>Authors' contributions</title> <p>S–YK conceived the study, performed sequencing of the samples, and contributed to the analysis and interpretation of the data as well as to the writing of the manuscript. J–HL collected relevant clinical data and assisted in preparation of the DNA samples. J–HY, M–YK and JSC participated in collection of samples, clinical analyses, and clinical diagnosis. S–YP participated in collection of samples and revised the manuscript. H–MR developed the study design, was responsible for overall supervision of all aspects of this research project and revised the manuscript. All authors read and approved the final manuscript.</p> <title>Pre-publication history</title> <p>The pre-publication history for this paper can be accessed here:</p> <p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2350/9/68/prepub"/></p>
<title>Acknowledgements</title> <p>This study was supported by the Korean Research Foundation Grant funded by the Korean Government (KRF-2005-041-E00222).</p>
<table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Clinical characteristics of normal controls and preeclamptic patients</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left">Characteristics</td><td align="center">Controls<break/>(n = 202)</td><td align="center">Patients<break/>(n = 170)</td><td align="center"><italic>p </italic>value*</td></tr></thead><tbody><tr><td align="left">Maternal age (y)</td><td align="center">32.8 ± 3.7</td><td align="center">30.9 ± 3.8</td><td align="center">&lt; 0.001</td></tr><tr><td align="left">Nulliparity (%)</td><td align="center">94 (46.5)</td><td align="center">139 (81.8)</td><td align="center">&lt; 0.001<sup>†</sup></td></tr><tr><td align="left">Systolic BP (mmHg)</td><td align="center">121.8 ± 10.2</td><td align="center">159.2 ± 16.6</td><td align="center">&lt; 0.001</td></tr><tr><td align="left">Diastolic BP (mmHg)</td><td align="center">75.3 ± 8.7</td><td align="center">100.5 ± 11.8</td><td align="center">&lt; 0.001</td></tr><tr><td align="left">Maternal weight at delivery (kg)</td><td align="center">68.0 ± 7.8</td><td align="center">74.2 ± 10.3</td><td align="center">&lt; 0.001</td></tr><tr><td align="left">GA at delivery (wk)</td><td align="center">39.1 ± 1.3</td><td align="center">36.5 ± 3.3</td><td align="center">&lt; 0.001</td></tr><tr><td align="left">Birth weight (g)</td><td align="center">3356.9 ± 436.1</td><td align="center">2528.0 ± 776.4</td><td align="center">&lt; 0.001</td></tr><tr><td align="left">Proteinuria (dipstick)</td><td align="center">-</td><td align="center">2.6 ± 1.0</td><td align="center">-</td></tr><tr><td align="left">IUGR (number)</td><td align="center">-</td><td align="center">58</td><td align="center">-</td></tr></tbody></table></table-wrap> <table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Allele frequencies of the Flt-1 (TG)<sub>n </sub>polymorphism in normal controls and preeclamptic patients</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center">Allele</td><td align="center">TG repeat</td><td align="center">Controls</td><td align="center">Patients</td></tr><tr><td/><td/><td colspan="2"><hr/></td></tr><tr><td/><td align="center">(PCR product length, bp)</td><td align="center">2n (%)</td><td align="center">2n (%)</td></tr></thead><tbody><tr><td align="center">A1</td><td align="center">12 (102)</td><td align="center">2 (0.50)</td><td align="center">0 (0.00)</td></tr><tr><td align="center">A2</td><td align="center">13 (104)</td><td align="center">4 (0.99)</td><td align="center">4 (1.18)</td></tr><tr><td align="center">A3</td><td align="center">14 (106)</td><td align="center">279 (69.06)</td><td align="center">217 (63.82)</td></tr><tr><td align="center">A4</td><td align="center">15 (108)</td><td align="center">3 (0.74)</td><td align="center">2 (0.59)</td></tr><tr><td align="center">A5</td><td align="center">16 (110)</td><td align="center">1 (0.25)</td><td align="center">0 (0.00)</td></tr><tr><td align="center">A6</td><td align="center">17 (112)</td><td align="center">0 (0.00)</td><td align="center">0 (0.00)</td></tr><tr><td align="center">A7</td><td align="center">18 (114)</td><td align="center">0 (0.00)</td><td align="center">0 (0.00)</td></tr><tr><td align="center">A8</td><td align="center">19 (116)</td><td align="center">5 (1.24)</td><td align="center">3 (0.88)</td></tr><tr><td align="center">A9</td><td align="center">20 (118)</td><td align="center">2 (0.50)</td><td align="center">6 (1.76)</td></tr><tr><td align="center">A10</td><td align="center">21 (120)</td><td align="center">96 (23.76)</td><td align="center">97 (28.53)</td></tr><tr><td align="center">A11</td><td align="center">22 (122)</td><td align="center">8 (1.98)</td><td align="center">7 (2.06)</td></tr><tr><td align="center">A12</td><td align="center">23 (124)</td><td align="center">4 (0.99)</td><td align="center">4 (1.18)</td></tr></tbody></table></table-wrap> <table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Genotype frequency of the Flt-1 (TG)<sub>n </sub>polymorphism in normal controls and preeclamptic patients</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left">Genotype</td><td align="center">Controls</td><td align="center">Patients</td><td align="center">OR (95% CI)</td><td align="center"><italic>p </italic>value</td></tr><tr><td/><td colspan="2"><hr/></td><td/><td/></tr><tr><td/><td align="center">n (%)</td><td align="center">n (%)</td><td/><td/></tr></thead><tbody><tr><td align="left">(TG)<sub>14</sub>/(TG)<sub>14</sub></td><td align="center">91 (45.05)</td><td align="center">65 (38.24)</td><td align="center">1.11 (0.59–2.09)</td><td align="center">0.746<sup>a</sup></td></tr><tr><td align="left">(TG)<sub>14</sub>/(TG)<sub>21</sub></td><td align="center">76 (37.62)</td><td align="center">71 (41.76)</td><td align="center">0.85 (0.45–1.60)</td><td align="center">0.613<sup>b</sup></td></tr><tr><td align="left">(TG)<sub>21</sub>/(TG)<sub>21</sub></td><td align="center">6 (2.97)</td><td align="center">11 (6.47)</td><td align="center">0.43 (0.14–1.35)</td><td align="center">0.143<sup>c</sup></td></tr><tr><td align="left">Other</td><td align="center">29 (14.36)</td><td align="center">23 (13.53)</td><td align="center">-</td><td align="center">-</td></tr><tr><td align="left">Combination</td><td align="center">111 (54.95)</td><td align="center">105 (61.77)</td><td align="center">1.32 (0.87–2.01)</td><td align="center">0.185<sup>d</sup></td></tr></tbody></table></table-wrap>
<table-wrap-foot><p>BP = blood pressure; GA = gestational age; IUGR = intrauterine growth retardation</p><p>A <italic>p </italic>value was calculated using the *Student's <italic>t</italic>-test or <sup>†</sup>Chi-Squared test.</p><p>Significant value was taken at the level of <italic>p </italic>&lt; 0.05.</p></table-wrap-foot> <table-wrap-foot><p>OR = odds ratios; CI = confidence interval.</p><p>Other, any genotypes other than the (TG)<sub>14</sub>/(TG)<sub>14</sub>, (TG)<sub>14</sub>/(TG)<sub>21</sub>, or (TG)<sub>21</sub>/(TG)<sub>21 </sub>genotype.</p><p>Combination, combined genotype [(TG)<sub>14</sub>/(TG)<sub>21</sub>+(TG)<sub>21</sub>/(TG)<sub>21</sub>+Other].</p><p>A <italic>p </italic>value was calculated using the Chi-Squared test or Fisher's exact test.</p><p>Significant value was taken at the level of <italic>p </italic>&lt; 0.05.</p><p><sup>a</sup>(TG)<sub>14</sub>/(TG)<sub>14 </sub>versus Other.</p><p><sup>b</sup>(TG)<sub>14</sub>/(TG)<sub>21 </sub>versus Other.</p><p><sup>c</sup>(TG)<sub>21</sub>/(TG)<sub>21 </sub>versus Other.</p><p><sup>d</sup>(TG)<sub>14</sub>/(TG)<sub>14 </sub>versus Combination.</p></table-wrap-foot>
[{"surname": ["Cuningham", "Gant", "Leveno", "Gilstrap", "Hauth", "Wenstrom"], "given-names": ["FG", "NF", "KJ", "LC", "JC", "KD"], "suffix": ["III"], "source": ["Williams Obstetrics"], "year": ["2001"], "edition": ["21"], "publisher-name": ["McGraw-Hill"], "fpage": ["568"], "lpage": ["570"]}, {"article-title": ["Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy"], "source": ["Am J Obstet Gynecol"], "year": ["2000"], "volume": ["183"], "fpage": ["S1"], "lpage": ["S22"], "pub-id": ["10.1067/mob.2000.107928"]}]
BMC Med Genet. 2008 Jul 17; 9:68